Wexford Capital LP Acquires New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Wexford Capital LP bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 14,000 shares of the biopharmaceutical company’s stock, valued at approximately $421,000.

Other large investors have also recently bought and sold shares of the company. Barclays PLC boosted its holdings in shares of TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after purchasing an additional 158,323 shares during the period. Nisa Investment Advisors LLC increased its position in TG Therapeutics by 52.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 8,112 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 2,803 shares during the period. Daymark Wealth Partners LLC increased its position in TG Therapeutics by 1.7% during the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company’s stock worth $1,249,000 after acquiring an additional 689 shares during the period. Avaii Wealth Management LLC increased its holdings in TG Therapeutics by 4.9% in the 4th quarter. Avaii Wealth Management LLC now owns 30,393 shares of the biopharmaceutical company’s stock valued at $915,000 after buying an additional 1,409 shares during the period. Finally, Kingswood Wealth Advisors LLC bought a new stake in shares of TG Therapeutics in the 4th quarter worth about $228,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $40.80.

TG Therapeutics Stock Performance

Shares of TGTX opened at $34.36 on Monday. The stock’s 50-day simple moving average is $38.59 and its 200 day simple moving average is $34.03. TG Therapeutics, Inc. has a 52-week low of $15.16 and a 52-week high of $46.48. The stock has a market capitalization of $5.45 billion, a price-to-earnings ratio of -343.57 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics’s revenue was up 90.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.07) earnings per share. Research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.